Abstract

Dyslipidemia is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD). Traditionally, total cholesterol has been used for ASCVD risk stratification and LDL-cholesterol, as a treatment target. However, these markers do not always explain the residual risk. According to the current dyslipidemia guidelines, assessment of novel lipid markers, e.g. lipoprotein (a) and apolipoprotein B, is recommended for better evaluation of the ASCVD risk and guidance in therapy.